anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy. Most patients receiving the combination of two RAS inhibitors do not obtain any additional benefit compared to monotherapy. In general, avoid combined use of RAS inhibitors. Closely monitor blood pressure, renal function and electrolytes in patients on Edarbyclor and other agents that affect the RAS.

Do not coadminister aliskiren with Edarbyclor in patients with diabetes. Avoid use of aliskiren with Edarbyclor in patients with renal impairment (GFR <60 mL/min).
Participants enrolled in the starting dose cohort will receive 300 mg Olaparib orally, twice a day (BID) on day 1 and day 14 for each 28-day cycle. Participants will also receive 35/100mg ASTX727 on days 1, and 3 of the 28-day cycle. Participants may continue study treatment indefinitely until disease progression unacceptable toxicity, withdrawal, or study closure; whichever comes first. If no DLTs are reported for the first 3 participants, an additional dose escalation cohort may open at the next dose level.
Study volunteers will listen to an audio recording of the Natural History of Selborne across each session.This 6 session intervention is meant to provide the control attention to the facilitator, room setting, social support, conditioning, and the time elapsed during the other respective interventions. We do not expect that this group will demonstrate significant cerebral blood flow changes as a function of the intervention.
The invention discloses Lycium ruthenicum Murr effective extract and its extraction method and use. The extraction method comprises the following steps of carrying out vacuum drying of Lycium ruthenicum Murr, crushing it, adding 95% of ethanol into the crushed Lycium ruthenicum Murr, carrying out backflow 2 times, wherein each backflow process lasts for 1h, carrying out filtration, carrying out distillation of the filtrate at a temperature of 75 DEG C for concentration, transferring the concentrate into an evaporating dish, carrying out water-bath evaporation, carrying out vacuum drying at a temperature of 70 DEG C for 2h to obtain dry extract, adding methanol into the dry extract until a constant volume is realized, filtering by an organic microporous filter membrane having the aperture size of 0.45 microns and carrying out procyanidine extraction. The Lycium ruthenicum Murr effective extract obtained by the scientific and reasonable extraction method has novel purposes of reducing blood pressure, blood fat and blood sugar. The extraction method provides a novel measure for effective and full utilization of the Lycium ruthenicum Murr effective extract in products for treating or preventing diabetes, hyperlipidemia and hypertension. The extraction method shortens extraction separation time, reduces energy consumption in processes, and effectively reduces a production cost. The Lycium ruthenicum Murr effective extract has high purity, stable performances, fewer extract impurities and good quality. The extraction method adopts pharmaceutical health-care products having antioxidation effects.
FIELD: medicine, pharmacy. SUBSTANCE: invention relates to the development of novel medicinal preparations of semithicone. Anti-foaming semithicone preparation as an oral, solid, medicinal form is prepared from freely flowing granulated composition comprising mixture consisting of simethicone or bicalcium phosphate or their mixture and one or some pharmaceutically acceptable excipients wherein mixture simethicone/calcium phosphate represents homogenous granulated composition with particles size 1 000 micron, not above. Composition can contain additionally silicon dioxide or anhydrous calcium phosphate as an adsorbing agent. The development of preparation allows expanding assortment of effective antifoaming and meteorism-eliminating medicinal agents. EFFECT: valuable properties of composition. 9 cl, 1 tbl, 6 ex
PURPOSE:To obtain a cosmetic having excellent protecting effects on ultraviolet rays and enhancing effects on suppression of erythema, containing a cosmetic material prepared by previously coating the surface of inorganic powder, inorganic spherical powder or organic spherical powder with an ultraviolet light absorber and bonding. CONSTITUTION:A cosmetic containing a cosmetic material prepared by previously coating the surface of inorganic powder (e.g. zinc oxide, kaolin or talc), inorganic spherical powder (e.g. spherical calcium silicate or spherical silica gel) or organic spherical. powder (e.g. nylon powder or crystal cellulose) with an ultraviolet light absorber (e.g. benzoic acid-based, salicylic acid-based, cinnamic acid-based or benzophenone-based ultraviolet light absorber) and bonding. The weight ratio of the powder and the ultraviolet light absorber in the cosmetic composition is preferably 95:5-60:40, especially 80:20-70:30. The amount of the cosmetic material added is preferably 2-60wt.% based on the total amounts of cosmetic. The cosmetic has excellent ultraviolet light protecting effects.
Developmental dyslexia, a neurodevelopment reading disorder, can impact even children with average intelligence. The present study examined the brain connectivity in dyslexic and control children during the reading task using graph theory. 19-channel electroencephalogram (EEG) signals were recorded from 15 dyslexic children and 15 control children. Functional connectivity was estimated by measuring the EEG coherence at 19 electrode locations, and graph measures were calculated using the graph theory method. Reading task results identified deprived task performance in dyslexic children against controls. Graph measures revealed longer path length, reduced clustering coefficient and reduced network efficiencies (in theta and alpha bands) of dyslexic group. At the nodal level, we found a significant increase in delta strength (T4 and T5 electrode locations) and reduced strength in theta (T6, P4, Fp1, F8 and F3) and alpha bands (T4, T3, P4 and F3) during the reading task in dyslexic group. In conclusion, the present study identified distinct graph measures between groups when performing a reading task and showed possible evidence for compromised brain networks in dyslexic group.
Many people with schizophrenia spectrum disorders (SSDs) experience profound amotivation, which is strongly related to anticipatory anhedonia. Yet, the neuropsychological fundamentals of anticipatory anhedonia and amotivation are barely understood, resulting in a lack of effective treatments for these patients. Aberrancies in positive mental imagery may interfere with the anticipation of pleasure and could thus explain anticipatory anhedonia and amotivation. However, the nature of mental imagery and its relationship with amotivational psychopathology in SSD is largely unknown. In this preregistered study, we therefore examined mental imagery characteristics and their relation to anticipatory anhedonia, amotivation, and daily life activity in SSD. TheN = 86 participants included individuals with SSD (n = 43) and demographically matched healthy controls (n = 43). Mental imagery, anticipatory pleasure, amotivation, and activity engagement were assessed with structured interviews and self-report questionnaires. Ecological momentary assessment was used to measure state anticipatory pleasure and activity engagement in daily life (n = 81). Compared to the control group, the SSD group showed comparable quantity, but less vividness of mental imagery. Reduced vividness of mental imagery in SSD was significantly associated with higher anticipatory anhedonia, amotivation, and low activity engagement in cross-sectional and prospective analyses. Reduced mental imagery vividness may cause a lack of internal incentive to seek pleasurable experiences and could explain amotivation. Interventions aiming to improve mental imagery vividness and related anticipatory pleasure responses in SSD may be effective in targeting amotivation.
The control group will be given pure water 800 mL of one of the drinks the night before surgery, between 1900 and 2400 h, and another 400 ml in the morning of the operation day. The last drink will be no later than 3 hours before the scheduled induction of anesthesia. Of note, the last meal on the day before the operation will be no later than 1800 h. Following this meal, no food or drink will be allowed except pure water.
A wealth of evidence intimates a profound connection between the immune system and osteonecrosis, albeit the specific immune factors underlying this connection remain largely veiled. A bidirectional Mendelian randomization (MR) study was conducted based on genome-wide association study summary data to identify causal links between 731 immune factors and osteonecrosis including drug-induced osteonecrosis. Preliminary MR analysis was accomplished utilizing the inverse-variance weighted method under a multiplicative random effects model, and heterogeneity and potential horizontal pleiotropy were evaluated through Cochrane's Q-test, MR-Egger intercept test, MR-PRESSO global test, and leave-one-out analysis. Upon false discovery rate correction, the gene-predicted level of one immune factor (CD62L - monocyte %monocyte) exhibited a significant positive correlation with osteonecrosis, while eight immune traits associated with monocytes, dendritic cells, and NK cells demonstrated significant causal effects with drug-induced osteonecrosis. Reverse MR revealed no significant correlations. This MR research provides genetic evidence for the causal associations between a broad spectrum of immune factors and osteonecrosis. Such a study aids in unraveling the intricate interaction patterns between the immune and skeletal systems, elucidating the pathogenesis of osteonecrosis, and identifying potential novel therapeutic approaches.
ETHNOPHARMACOLOGICAL RELEVANCE: Chaihu-Shugan-San (CSS) is a classic traditional Chinese medicine (TCM) formula from the Ming Dynasty "Jingyue's Complete Works". In China, it is prevalent for the treatment of a wide range of ailments, with a particular emphasis on functional gastrointestinal disorders (FGIDs). Clinical evidence suggests that CSS has been found to be a highly effective therapeutic approach for the treatment of Functional Dyspepsia (FD), however, there is a limited amount of high-quality clinical evidence, particularly randomized, double-blind, placebo-controlled trials to support this claim.
AIM OF THE STUDY: To evaluate the therapeutic efficacy of Chaihu-Shugan-San (CSS) for treating functional dyspepsia (FD) by comparing it to placebos, as well as to investigate the impact of CSS on the gut microbiota in individuals diagnosed with FD.
MATERIALS AND METHODS: This was a randomized double-blind, placebo-controlled clinical trial implemented at Shuguang Hospital in Shanghai. Between May 2021 and December 2022, 94 participants satisfying the Rome IV diagnostic criteria for FD were enrolled. They were assigned randomly to either the CSS group or the placebo group, with an equal allocation ratio of 1:1. Patients in both groups received the intervention for four weeks. The primary outcome was the dyspepsia symptom scores evaluated by using single dyspepsia symptom scale (SDS) after four weeks of treatment. The secondary outcomes were the solid gastric empties rate measured by a barium strip method, Hamilton anxiety scale (HAMA), Hamilton depression scale (HAMD), and Functional dyspepsia Quality of life scale (FDDQL). In addition, after unblinding, 30 patients in the CSS group were randomly selected and divided into before and after treatment of the FD groups (FD1, FD2), and 30 healthy participants were selected as healthy control group (HC), and the gut microbiota was analyzed by 16S rRNA sequencing.
RESULTS: After four weeks of treatment, the SDS score exhibited a significant improvement in the CSS group compared to the placebo group (t = 4.882; P <0.001). The difference in barium strip gastric emptying rate in the CSS group showed a significant ascent compared to the control group (P < 0.01). The HAMA, HAMD, and FDDQL scores in the CSS group showed a statistically significant increase compared to the control group (all P < 0.01). The results of 16S rRNA sequencing revealed that FD patients had less diverse and abundant microbiota than the healthy people. Additionally, the application of CSS resulted in the modulation of certain bacterial populations, leading to both up-regulation and down-regulation of their quantities.
CONCLUSIONS: These findings suggested that CSS is more effective compared to a placebo in treating FD, relieves anxiety and depression, increases gastric emptying rate in FD patients, and that CSS also affects the bacterial community structure in FD patients.
TRIAL REGISTRATION: ChiCTR, ChiCTR2100045793. Registered 25 Mach 2021.
PROBLEM TO BE SOLVED: To provide a tacky adhesive sheet having a print layer which has excellent adhesiveness by comprising: a base film formed of a soft PVC contg. a plasticizer; an acrylic resin layer and a print layer, with a particular ink printed thereon, provided on the front surface of the base film; and a tacky adhesive layer provided on the back surface of the base film. SOLUTION: An about 0.0001 to 0.01mm-thick acrylic resin layer 2 is coated on the front surface side of an about 0.03 to 0.25mm-thick base film 1 formed of a soft PVC comprising 100 pts.wt. (hereinafter referred to as 'pts.') PVC and about 30 to 60 pts. plasticizer, such as a phthalic ester, incorporated into the PVC. A print layer 3 with an ultraviolet-curable ink printed thereon is laminated thereon. Besides, an about 0.05mm-thick tacky adhesive layer 4 is laminated onto the back surface side of the base film 1 to prepare a tacky adhesive sheet A.  Alternatively, the tacky adhesive sheet may be prepd. by forming a print layer, with an ultraviolet-curable ink printed thereon, on the front surface side of a base film comprising 100 pts.wt. polyurethane-PVC graft copolymer and 1 to 20 pts. styrene-ethylene-butadiene-styrene resin and laminating a tacky adhesive layer onto the back surface side of the base film.
Neonatal hypoxic-ischemic encephalopathy (HIE) refers to brain injury resulting from reduced blood and oxygen flow to a baby's brain near the time of birth. HIE affects up to 12,000 newborns each year in the U.S. Half of affected infants have a bad outcome including death, cerebral palsy and cognitive impairment despite receiving hypothermia, the only available treatment. Erythropoietin (Epo) is a cytokine with remarkable neuroprotective and neuroregenerative effects demonstrated in animal models of neonatal brain injury. In a phase I trial of Epo + hypothermia, the investigators found that Epo 1000 U/Kg/dose best reproduced the pharmacokinetics of neuroprotective dosing in animal models. Long term outcomes were better than expected based on entry criteria and MRI findings. A phase II trial compared 50 cooled infants randomized to receive Epo or placebo. Infants treated with hypothermia + Epo had less brain injury on early MRI, and better 12-month motor development. The investigators hypothesize that Epo given to cooled infants with moderate/severe HIE will reduce the combined primary outcome of death or neurodevelopmental impairment from 49 to 33%. This is a randomized, double-blind, placebo-controlled trial of Epo therapy in 500 infants with HIE undergoing hypothermia. Specific aims are 1) To determine if 5 doses of Epo 1000 U/kg IV reduces the rate of death, motor or cognitive deficits at 2 years; 2) To assess safety of Epo by evaluating clinical toxicity; and 3) To determine whether Epo decreases the severity of neonatal brain injury as evidenced by early MRI and circulating biomarkers of brain injury. The investigators anticipate that Epo will confer improved 2-year neurodevelopmental outcome, will be safe, and will decrease brain injury severity as determined by early biomarkers.
A cold coating process that may usefully be applied to pharmaceutical tablets and the like comprises providing cores with two or more coatings comprising a syrup coating and one or more additional coatings of syrup and/or powder wherein, in at least one coating stage syrups and/or powders are used which contain finely-divided oxides of metals or silicon which have been formed as an aerosol by thermal decomposition of suitable volatile compounds in the vapour or gaseous phase in the presence of agents having an oxidizing or hydrolysing action and are recovered as an aerogel and which have a particle size smaller than 200 mm . Suitable metal oxides are aluminium oxide or titanium dioxide.  In the coating process, the cores may be coated initially with a syrup containing the oxide, or with a conventional syrup coating and then have an application of a coating powder containing the oxide, or with a conventional syrup coating and then have an application of a coating powder containing the necessary oxide. The presence of the oxide in the coatings speeds up the drying times and results in a much quicker coating process than possible hitherto.  In an example, cores were coated with a syrup comprising gelatina alba 15 parts, distilled water 50 parts, mucilago gummi arabic 130 parts, saccharin syrup (70 per cent) 805 parts; the syrup coated cores were then dusted with a powder comprising calcium carbonate 35 parts, silica 16 parts, talc 25 parts, saccharin 20 parts and gum arabic 4 parts.  These coating stages may be repeated as often as required to build up a sufficient coating thickness.
Sensory entrained TMS (seTMS) is a combination of music and TMS to align brain oscillations and enhance the effects of TMS. seTMS will be delivered to determine target engagement to noninvasive seTMS brain stimulation compared to standard TMS. TMS will be delivered using neuro-navigation based on participant's own MRI images. Intensity will be set to 120% of the participant's motor threshold. Participants will be monitored during the session for adverse events and/or side effects.
FIELD: organic chemistry, pharmacy. SUBSTANCE: invention describes new derivatives of piperazine of the general formula (I) where A is an alkylene chain with 2-5 carbon atoms; R 1  - phenyl substituted with lower alkoxy-group; R 2  - phenyl; R 3  is C 3 -C 7 -cycloalkyl, or its pharmaceutically acceptable acid-additive salts. They are antagonists of 5-HT 1A  receptors and can be used for treatment of patients with fear. Method of synthesis of the above indicated compounds involves an interaction of compound HN(R 2 )COR 3  with alkylating agent containing a group   where values A, R 1 , R 2 , R 3  are indicated above. Invention describes also a pharmaceutical composition on the basis of the above indicated compounds. EFFECT: improved method of synthesis, enhanced effectiveness of compounds. 9 cl, 2 ex
The study is designed in three phases, employing a mixed-method approach that integrates qualitative and quantitative methods. Phase 1 involves exploring the alignment of the Dice Model of Play with the experiences of 10 children (aged 3-8, diagnosed with physical disabilities) and their guardians through semi-structured interviews and content analysis; Phase 2 examines the practical application of the model with a cross-over design. Ten children will build their Lego robots within a co-design and will play with that robot for four sessions. The other group will play with conventional toys for four sessions. They will switch after finishing those sessions. Sessions will be directed by a master of occupational therapy student supervised by Dr. Jacquie Ripat, a registered occupational therapist in Manitoba. Assessments will be Test of Playfulness (TOP), enjoyment (PPE_DC), and play skills (ChIPPA-2) three times at the start, switching point, and last session. A go-along interview will be conducted in the co-design. Lastly, Phase 3 seeks expert opinions on the revised Dice Model of Play's clarity, relevance, and applicability, using online focus groups with professionals in occupational therapy, psychology, and computer science. The study aims to modify and enhance the model based on the findings from these phases.
Systemic sclerosis (SSc) is a rare and highly heterogeneous chronic autoimmune disease characterized by multi-organ and tissue fibrosis, often accompanied by a poor prognosis and high mortality rates. The primary pathogenic mechanisms of SSc are considered to involve tissue fibrosis, autoimmune dysfunction, and microvascular abnormalities. Recent studies have shed light on the gut microbiota (GM) and metabolites in SSc patients, revealing their association with gastrointestinal symptoms and disease phenotypes. However, further elucidation is needed on the specific mechanisms underlying the interactions between GM, metabolites, and the immune system and their roles in the pathogenesis of SSc. This review outlines the characteristics of GM and metabolites in SSc patients, exploring their interrelationships and analyzing their correlations with the clinical phenotypes of SSc. The findings indicate that while the α-diversity of GM in SSc patients resembles that of healthy individuals, notable differences exist in the β-diversity and the abundance of specific bacterial genera, which are closely linked to gastrointestinal symptoms. Moreover, alterations in the levels of amino acids and lipid metabolites in SSc patients are prominently observed and significantly associated with clinical phenotypes. Furthermore, this review delves into the potential immunopathological mechanisms of GM and metabolites in SSc, emphasizing the critical role of interactions between GM, metabolites, and the immune system in comprehending the immunopathological processes of SSc. These insights may offer new scientific evidence for the development of future treatment strategies.
Patients with TBI who require inpatient rehabilitation are frequently confused at the time of admission for rehabilitation. Our investigations of confusion conducted as part of the TBIMSM have clarified the nature of confusion in early recovery after TBI. Early confusion (PTCS) has been found to be a complex syndrome characterized by disorientation, cognitive impairment, restlessness, decreased level of daytime arousal, sleep disturbance, fluctuation of symptoms, and psychotic-type symptoms. PTCS complicates early management of patients with TBI, and may contribute to increased risk of injury to patients and hospital staff, increased stress among family members and staff, decreased participation in therapies, increased cost of care, and an increased likelihood of being discharged to psychiatric or long-term care settings. These facts indicate the need for effective management of PTCS. Consensus regarding optimal treatment of the cognitive and behavioral symptoms encountered among patients with PTCS does not exist currently. While many agents have been tried to address such symptoms in TBI, few have been investigated systematically. These circumstances indicate the need for appropriate clinical trials to provide guidance to clinicians for medical treatment of PTCS. In response, the NIDRR-Traumatic Brain Injury Model System of Mississippi proposed a randomized, double-blinded, placebo-controlled, parallel group trial for the pharmacological treatment of PTCS. The agent selected for this clinical trial is amantadine, an NMDA and indirect dopamine agonist. This agent will be compared to placebo on response measures of efficacy and safety.

Study hypothesis: Amantadine will reduce the severity and number of symptoms of PTCS.